

NCIC CLINICAL TRIALS GROUP

**SARCOMA**

DISEASE SITE  
NCIC CTG SARCOMA / CANADIAN SARCOMA GROUP  
COMMITTEE MEETING  
AGENDA

Delta Chelsea Hotel, Toronto, Ontario  
Sunday, April 29, 2007 – 1:30 p.m. – 4:00 p.m. EST  
Room: Carlyle

Chair: V. Bramwell

---

1:30 p.m.	<b>WELCOME AND MINUTES – 30 APRIL 2006</b>	V. Bramwell
	<b>REPORT FROM EXECUTIVE COMMITTEE</b> Draft Sarcoma DSC component of NCIC CTG	V. Bramwell
2:15 p.m.	<b>DISSOLUTION OF ICAS</b> Implications for Sarcoma DSC / CSG	V. Bramwell / Q. Chu
2:45 p.m.	<b>NEW PROPOSALS</b> NCIC CTG SCR.4/SWOG S0505: Sorafenib in advanced STS NCIC CTG SCR.5/SWOG S0502: Imatinib ± bevacizumab in advanced GIST NCIC CTG ? IND: Dasatinib in advanced STS	V. Bramwell V. Bramwell Q. Chu
3:15 p.m.	<b>STUDIES ONGOING / CLOSE TO ACTIVATION</b> NCIC CTG / CSG SCR.1 / ASCOG Z9001: Adjuvant Imatinib NCIC CTG / CSG SR.5 / EORTC 62012: DOX vs HD DOX / IFOS advanced STS	M. Blackstein S. Rorke
3:30 p.m.	<b>COMPLETED STUDIES</b> NCIC CTG / CSG IND.136: Flavopiridol in STS Closed November 2000 NCIC CTG / CSG SR.4 / SWOG S0033: Imatinib in GIST Closed September 2001 NCIC CTG / CSG SR.3 / EORTC 62931: Adjuvant DOX / IFOS Closed December 2003	D. Morris V. Bramwell V. Bramwell
	<b>OTHER BUSINESS</b>	
4:00 p.m.	<b>ADJOURN</b>	